Get the Stockscreener App
3.14
0.16%
-0.02
Q 32 Bio Inc stock is traded at $3.14, with a volume of 77,276.
It is down -0.16% in the last 24 hours and down -10.62% over the past month.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
See More
Previous Close:
$3.16
Open:
$3.16
24h Volume:
77,276
Relative Volume:
0.22
Market Cap:
$37.94M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+4.13%
1M Performance:
-10.62%
6M Performance:
-92.13%
1Y Performance:
+0.00%
1-Day Range:
$3.08
$3.21
1-Week Range:
$2.90
$3.46
52-Week Range:
$2.90
$53.79
Q 32 Bio Inc Stock (QTTB) Company Profile
Name
Q 32 Bio Inc
Sector
Industry
Phone
781-999-0232
Address
830 WINTER STREET, WALTHAM
Compare QTTB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
3.155 | 37.94M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.05 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.60 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.00 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.24 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.44 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | Raymond James | Strong Buy |
| Sep-11-24 | Initiated | Wells Fargo | Overweight |
| Jun-17-24 | Initiated | Guggenheim | Buy |
| May-21-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-22-22 | Reiterated | BTIG Research | Neutral |
| Feb-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-22-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-02-21 | Initiated | Stifel | Hold |
| Dec-14-20 | Resumed | H.C. Wainwright | Buy |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-16-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-24-20 | Initiated | Chardan Capital Markets | Buy |
| Nov-01-19 | Initiated | Oppenheimer | Perform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
View All
Q 32 Bio Inc Stock (QTTB) Latest News
Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference - The Eastern Progress Online
QTTB stock touches 52-week low at $2.95 amid market challenges - MSN
Barclays PLC Acquires 5,353 Shares of Q32 Bio Inc. (NASDAQ:QTTB) - Defense World
Q32 Bio Inc. (NASDAQ:QTTB) Receives $29.86 Consensus Target Price from Brokerages - Defense World
Q32 Bio Advances Clinical Trials for Growth Opportunities - TipRanks
Pre-market Movers: ONCO, EYEN, SGMO, VSTM... - RTTNews
Q32 Bio Inc (QTTB) Could Be Worth Considering For The Next Few Weeks - Stocks Register
Arq Inc (ARQ) Analyst Thoughts: How High Can It Go? - Stocks Register
Analysts Update Their Estimates For Brunswick Corp - Stocks Register
At $1.81 Price, XCHG Ltd ADR (XCH) Is Sitting And Waiting - Stocks Register
Analysts Update Their Estimates For EPR Properties - Stocks Register
Protagenic Therapeutics Inc’s (PTIX) -12.44% Retreat Justifies A Second Look - Stocks Register
LegalZoom.com Inc (LZ) Volatility Hits 3.83% – Here Is What You Should Do - Stocks Register
At $18.67 Price, Osisko Gold Royalties Ltd (OR) Is Sitting And Waiting - Stocks Register
First Foundation Inc (FFWM): A New Perspective - Stocks Register
Analyst Updating Price Targets And Ratings For Springview Holdings Ltd (SPHL) - Stocks Register
QTTB Stock Touches 52-Week Low at $3 Amid Market Challenges - Investing.com India
QTTB Stock Touches 52-Week Low at $3 Amid Market Challenges By Investing.com - Investing.com South Africa
What You Didn’t Know About Chipotle Mexican Grill (NYSE: CMG) This Week - Stocks Register
Q32 Bio (QTTB) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews
Geode Capital Management LLC Purchases 24,114 Shares of Q32 Bio Inc. (NASDAQ:QTTB) - Defense World
Jane Street Group LLC Acquires New Stake in Q32 Bio Inc. (NASDAQ:QTTB) - Defense World
Q32 Bio Inc. (NASDAQ:QTTB) Holdings Increased by Barclays PLC - Defense World
Franklin Resources Inc. Takes Position in Q32 Bio Inc. (NASDAQ:QTTB) - Defense World
NuScale Power Corporation (NYSE: SMR): An Enticing Stock To Watch - Stocks Register
Q32 Bio Inc. (NASDAQ:QTTB) Shares Bought by State Street Corp - Defense World
ARS Pharmaceuticals (NASDAQ:SPRY) vs. Q32 Bio (NASDAQ:QTTB) Head to Head Review - Defense World
Q32 Bio Inc. (NASDAQ:QTTB) Receives $29.86 Consensus Target Price from Analysts - Defense World
Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday - MSN
Q32 Bio: Oppenheimer slashes price target on mixed trial results - MSN
Q32 Bio's SWOT analysis: stock outlook shifts amid clinical setbacks By Investing.com - Investing.com Canada
Q32 Bio's SWOT analysis: stock outlook shifts amid clinical setbacks - Investing.com India
Q32 Bio pushes back Phase 2 trial of ADX-097 in AAV patients - ANCA Vasculitis News
StockWatch: Q32 Shares Crater 85% as Investors, Analysts Sour on Trial Results - Genetic Engineering & Biotechnology News
BMO Capital Markets Cuts Q32 Bio (NASDAQ:QTTB) Price Target to $22.00 - Defense World
Q32 Bio FY2025 EPS Estimate Lifted by Leerink Partnrs - Defense World
FY2025 EPS Estimates for Q32 Bio Boosted by Leerink Partnrs - MarketBeat
Q32 Bio shares target cut, rating held on clinical trial results - Investing.com Canada
Here's Why Q32 Bio Stock Hit A New Record Low On Wednesday - Barchart
Q32 Bio (NASDAQ:QTTB) Rating Lowered to Hold at Leerink Partnrs - MarketBeat
Q32 Bio price target lowered to $20 from $80 at Oppenheimer - Yahoo Finance
Candel leads biotech gainers amid wave of data readouts - BioCentury
QTTB Stock Touches 52-Week Low at $8.06 Amid Market Volatility - Investing.com India
Leerink revises Q32 Bio stock target as Phase 2 trials fail to meet expectations - Investing.com Canada
Q32 Bio stock target cut, rating held on trial results By Investing.com - Investing.com Nigeria
Q32 Bio shares downgraded as Ph2 trials reveal limited near-term upside potential - Investing.com Nigeria
Q32 stock craters 71% on mixed Phase 2 data for bempikibart (NASDAQ:QTTB) - Seeking Alpha
Q32 Bio stock target cut, rating held on trial results - Investing.com
Oppenheimer maintains Outperform on Q32 Bio stock with focus on renal basket study - Investing.com
Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday? - Benzinga
Q 32 Bio Inc Stock (QTTB) Financials Data
There is no financial data for Q 32 Bio Inc (QTTB). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Q 32 Bio Inc Stock (QTTB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Violette Shelia M. | Chief Scientific Officer |
Oct 11 '24 |
Option Exercise |
3.12 |
4,574 |
14,271 |
17,874 |
| Violette Shelia M. | Chief Scientific Officer |
Oct 08 '24 |
Option Exercise |
3.12 |
13,300 |
41,496 |
13,300 |
| TZIANABOS ARTHUR | Director |
Mar 25 '24 |
Sale |
24.20 |
265 |
6,413 |
7,983 |
| Alloway Paul | See Remarks |
Mar 25 '24 |
Sale |
24.21 |
268 |
6,488 |
2,596 |
| Michaud Charles Jr | See Remarks |
Mar 25 '24 |
Sale |
24.20 |
75 |
1,815 |
927 |
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):